{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:29:01Z","timestamp":1715646541292},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ajgponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jagp.2024.02.012","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T16:33:51Z","timestamp":1709397231000},"page":"678-680","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chasing Causality: Understanding the Link Between Benzodiazepine Exposure and Dementia Risk"],"prefix":"10.1016","volume":"32","author":[{"given":"Helmet T.","family":"Karim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2024.02.012_bib0001","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jagp.2023.10.002","article-title":"Cerebral metabolic signature of chronic benzodiazepine use in nondemented older adults: an FDG-PET study in the MEMENTO cohort","volume":"32","author":"Gallet","year":"2024","journal-title":"Am J Geriatr Psych"},{"key":"10.1016\/j.jagp.2024.02.012_bib0002","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psych"},{"key":"10.1016\/j.jagp.2024.02.012_bib0003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","article-title":"Benzodiazepine misuse in the elderly: risk factors, consequences, and management","volume":"18","author":"Airagnes","year":"2016","journal-title":"Curr Psych Rep"},{"key":"10.1016\/j.jagp.2024.02.012_bib0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1176\/appi.ajp.2019.19030315","article-title":"Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study","volume":"177","author":"Osler","year":"2020","journal-title":"Am J Psych"},{"key":"10.1016\/j.jagp.2024.02.012_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127836","article-title":"Association between benzodiazepine use and dementia: a meta-analysis","volume":"10","author":"Zhong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jagp.2024.02.012_bib0006","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neurobiolaging.2019.08.008","article-title":"Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the multidomain Alzheimer preventive trial cohort","volume":"84","author":"Desmidt","year":"2019","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jagp.2024.02.012_bib0007","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41386-021-01246-5","article-title":"Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F florbetapir PET study in the MEMENTO cohort","volume":"47","author":"Gallet","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jagp.2024.02.012_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/ajp.140.1.82","article-title":"A controlled clinical trial of alprazolam for the treatment of anxiety","volume":"140","author":"Rickels","year":"1983","journal-title":"Am J Psych"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748124002689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748124002689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T15:24:13Z","timestamp":1715613853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748124002689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1064748124002689"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2024.02.012","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chasing Causality: Understanding the Link Between Benzodiazepine Exposure and Dementia Risk","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2024.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}